Tag:
Avodart
Latest Headlines
Latest Headlines
Watson seeks to market generic Avodart
Watson Pharmaceuticals has confirmed that one of its units has filed an ANDA with the FDA seeking approval to market dutasteride capsules, 0.5 mg. The capsules are a generic version of
FDA denies cancer-prevention use for GSK's Avodart
GlaxoSmithKline won't get the chance to tout prostate drug Avodart as a cancer preventative, at least not yet. FDA declined to approve the cancer-prevention indication for the drug, which is
FDA panel dismisses prostate meds for cancer use
Broadening the use of two prostate drugs into cancer prevention didn't win a thumbs-up from FDA's expert advisors. After weighing the arguments over the last couple of days, the advisory committee
FDA disputes prostate drugs' risk-cutting power
An FDA advisory panel tomorrow will debate data on using prostate drugs to prevent cancer. The drugs in question are GlaxoSmithKline's ( $GSK ) Avodart and Merck's ( $MRK ) Proscar, and each has been
Journal supplement prompted apology from GSK
Last year, GlaxoSmithKline ( NYSE: GSK ) quietly backpedaled away from a marketing snafu that's now come to light. The company had sponsored a supplement to the journal Urology on prostate cancer--one
